Drug Trial Radar · NCT04972656
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
420
Planned (sponsor's estimate)
Start
Sep 5, 2022
Primary completion
Dec 30, 2025
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tianjin Medical University General Hospital
- First posted
- Jul 22, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.
Conditions
- Pulmonary Arterial Hypertension
Interventions
AmbrisentanDrug
Titration: Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration. Maximum dose allowed: not to exceed 10 mg/day. Administration: Ambrisentan will be administered orally with or without food intake.
PlaceboDrug
Placebo tablet (one to two tablets corresponding to one to two verum tablets). Administration: Placebo will be administrated orally with or without food intake in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of diagnostic PAH (mPAP ≥25 mmHg)Time frame: baseline, 1 year
- Change of Pulmonary vascular resistanceTime frame: baseline, 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing First Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.